Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HC101a
- Development stage
- Preclinical
- Lead developer
- HebeCell
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
HC101a is an off-the-shelf, induced pluripotent stem cell (iPSC)-derived natural killer (NK) cell therapy developed by HebeCell. It is produced using the proprietary ProtoNK™ platform, which utilizes a feeder-free, 3D suspension culture system to generate high-purity, functional NK cells from iPSCs. HC101a is specifically designed for the treatment of pulmonary metastasis in pediatric sarcoma. The therapy leverages the innate ability of NK cells to recognize and eliminate tumor cells through various activating receptors, providing a potential treatment option for metastatic solid tumors in children. The ProtoNK™ platform aims to overcome the limitations of donor-derived NK cells by providing a scalable and standardized source of therapeutic cells.
- Brand names
- ProtoNK
- Other names
- HC101a-HebeCell-cell therapy-ProtoNK™ (NK cells)-Pulmonary metastasis of pediatric sarcoma
Beyond the preview
Go deeper on HC101a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HC101a.